ArticleBMC public health2019
Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Economic evaluation of hepatitis B screening in low- and middle-income countries: a systematic review.International journal of clinical pharmacy · 2025Pooled it
- Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis.PLoS medicine · 2020Pooled it
- Global burden and forecast of acute viral hepatitis B among women of childbearing age: a systematic analysis of the global burden of disease study 2021.BMC infectious diseases · 2026Article
- Cost-effectiveness of tenofovir disoproxil fumarate prophylaxis for perinatal hepatitis B virus prevention in Ethiopia: a decision analytical modeling.BMC public health · 2025Article
- Effect of invasive tests during pregnancy on perinatal transmission of hepatitis B infection: a scoping review.EClinicalMedicine · 2025Review
- Accelerating the momentum to achieve global elimination of hepatitis B infection: a scoping review of hepatitis B guidelines to reduce mother to child transmission.EClinicalMedicine · 2025Review
- Article
- Antenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and Treatment.Open forum infectious diseases · 2024Article
- A new hepatitis B elimination strategy for remote populations is needed.The Lancet regional health. Western Pacific · 2024Article
- Global burden of hepatitis B virus: current status, missed opportunities and a call for action.Nature reviews. Gastroenterology & hepatology · 2023Review
- Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus.JHEP reports : innovation in hepatology · 2023Review
- Hepatitis B Virus Research in South Africa.Viruses · 2022Review
- The Lancet Commission on diagnostics: transforming access to diagnostics.Lancet (London, England) · 2021Review
- A global investment framework for the elimination of hepatitis B.Journal of hepatology · 2021Article
- Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis.BMC pregnancy and childbirth · 2021Article
- Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview.AIDS research and therapy · 2021Review
- An Automated, Quantitative, and Multiplexed Assay Suitable for Point-of-Care Hepatitis B Virus Diagnostics.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundInternational sustainable development goals for the elimination of viral hepatitis as a public health problem by 2030 highlight the need to optimize strategies for prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. An important priority for Africa is to have affordable, accessible and sustainable prevention of mother to child transmission (PMTCT) programmes, delivering screening and treatment for antenatal women and implementing timely administration of HBV vaccine for their babies.
methodsWe developed a decision-analytic model simulating 10,000 singleton pregnancies to assess the cost-effectiveness of three possible strategies for deployment of tenofovir in pregnancy, in combination with routine infant vaccination: S1: no screening nor antiviral therapy; S2: screening and antiviral prophylaxis for all women who test HBsAg-positive; S3: screening for HBsAg, followed by HBeAg testing and antiviral prophylaxis for women who are HBsAg-positive and HBeAg-positive. Our outcome was cost per infant HBV infection avoided and the analysis followed a healthcare perspective.
resultsBased on 10,000 pregnancies, S1 predicts 45 infants would be HBV-infected at six months of age, compared to 21 and 28 infants in S2 and S3, respectively. Relative to S1, S2 had an incremental cost of $3940 per infection avoided. S3 led to more infections and higher costs.
conclusionGiven the long-term health burden for individuals and economic burden for society associated with chronic HBV infection, screening pregnant women and providing tenofovir for all who test HBsAg+ may be a cost-effective strategy for South Africa and other low/middle income settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.